Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF 14.16
-0.28 (-1.94%)
Jul 31, 2026, 5:30 PM CET
SWX:SANN Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 77.19 | 39.12 | 103.41 | 7.47 | -1.6 | |
Revenue Growth | 97.32% | -62.17% | 1283.84% | - | - |
Cost of Revenue | 62.01 | 15.53 | 3.24 | 3.59 | 3.77 |
Gross Profit | 15.17 | 23.58 | 100.18 | 3.88 | -5.36 |
Selling, General & Admin | 30.77 | 30.5 | 30.97 | 25.42 | 22.06 |
Research & Development | 22.22 | 26.47 | 18.67 | 30.54 | 29.72 |
Other Operating Expenses | -0.2 | -0.27 | -18.31 | -0.1 | -0.25 |
Total Operating Expenses | 52.79 | 56.69 | 31.34 | 55.86 | 51.53 |
Operating Income | -37.61 | -33.11 | 68.84 | -51.98 | -56.89 |
Interest Income | 10.85 | 11.62 | 19.35 | 5.98 | 22.9 |
Interest Expense | -22.29 | -20.17 | -33.38 | -24.62 | -20.73 |
Total Non-Operating Income (Expense) | -11.44 | -8.55 | -14.02 | -18.64 | 2.17 |
Pretax Income | -49.05 | -41.66 | 54.82 | -70.62 | -54.72 |
Provision for Income Taxes | 0.19 | 0.31 | 0.04 | 0.46 | 0.81 |
Net Income | -49.24 | -41.97 | 54.78 | -71.08 | -55.53 |
Net Income to Common | -49.05 | -41.66 | 54.82 | -70.62 | -54.72 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 13 | 11 | 11 | 6 | 3 |
Shares Outstanding (Diluted) | 13 | 11 | 11 | 6 | 3 |
Shares Change | 14.29% | 4.24% | 79.29% | 78.31% | 156.61% |
EPS (Basic) | -3.78 | -3.69 | 5.18 | -11.67 | -16.20 |
EPS (Diluted) | -3.78 | -3.69 | 5.01 | -11.67 | -16.20 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -34.82 | -35.68 | 47.18 | -29.9 | -37.36 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Per Share | -2.68 | -3.13 | 4.32 | -4.91 | -10.93 |
Gross Margin | 19.66% | 60.29% | 96.87% | 51.93% | 336.18% |
Operating Margin | -48.73% | -84.64% | 66.57% | -695.52% | 3566.65% |
Profit Margin | -63.79% | -107.30% | 52.97% | -951.10% | 3481.25% |
FCF Margin | -45.11% | -91.21% | 45.62% | -400.05% | 2342.38% |
EBITDA | -31.93 | -27.46 | 71.89 | -42.12 | -53.16 |
EBITDA Margin | -41.37% | -70.21% | 69.51% | -563.60% | 3333.17% |
EBIT | -37.61 | -33.11 | 68.84 | -51.98 | -56.89 |
EBIT Margin | -48.73% | -84.64% | 66.57% | -695.52% | 3566.65% |
Effective Tax Rate | -0.38% | -0.75% | 0.07% | -0.65% | -1.48% |